Arie Belldegrun, Director at Allogene Therapeutics, Inc. (ALLO), bought 310,078 shares at $12.60 ($3.9M) on 2022-01-12, disclosed to the SEC on 2022-01-14.
Open-market purchase of $3.9M ALLO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.60 | 155,039 | $2.0M | 50.0% |
| 2 | $12.60 | 155,039 | $2.0M | 50.0% |
| Total | $12.60 avg | 310,078 | $3.9M | 100% |
| Filing → |
| ALLO | BUY | 2019-02-13 | $3.5M | — | Filing → |
| KITE | SELL | 2017-09-27 | $9.5M | — | Filing → |
| KITE | BUY | 2017-05-09 | $1.2M | — | Filing → |